Triple Negative Breast Cancer News and Research

RSS

Soft tumor environments prime cancer cells for survival during metastasis

Researchers have discovered how the mechanical properties of tumors can prime cancer cells to better survive their spread to other organs.

13 Apr 2024

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

10 Apr 2024

Study reveals immune cell levels as prognostic marker in early-stage triple-negative breast cancer

A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.

2 Apr 2024

New method for detecting and treating breast cancer subtypes

The most prevalent disease in women, breast cancer, poses a major risk to the health of women.

2 Apr 2024

New DNA nanomachine targets breast cancer with precision

Breast cancer is the most common malignancy in women, posing a serious threat to the female health. Due to the high inter- and intra-tumoral heterogeneity of breast cancer, clinical treatment and prognosis can vary greatly in patients.

28 Mar 2024

Newly discovered molecule may be a potential therapeutic target for triple-negative breast cancer

A team of researchers from Hiroshima University has discovered a molecule that promotes the production of cancer cells. This molecule may prove to be a potential therapeutic target in the treatment of triple-negative breast cancer, an aggressive form of breast cancer.

27 Mar 2024

Genetic test can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy

Researchers have developed a genetic test that can identify how patients with triple negative early-stage breast cancer will respond to immunotherapy drugs.

20 Mar 2024

Exploring the power of diet: A new frontier in disease management and cancer treatment

The therapeutic potential of and molecular mechanisms through which dietary interventions impact a wide range of human diseases.

13 Mar 2024

New “GPS nanoparticle” delivers a genetic punch to the protein implicated in tumor spread

A newly developed "GPS nanoparticle" injected intravenously can home in on cancer cells to deliver a genetic punch to the protein implicated in tumor growth and spread, according to researchers from Penn State.

11 Mar 2024

Sacituzumab govitecan plus platinum-based chemotherapy effective in multiple carcinomas

A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas."

5 Mar 2024

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

21 Feb 2024

Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

14 Feb 2024

Study links specific inflammatory markers to increased cancer risk

The causal relevance of circulating inflammatory markers in cancer risk.

5 Feb 2024

UH researcher aims to revolutionize treatment regimens for triple-negative breast cancer

A researcher at the University of Houston College of Pharmacy Drug Discovery Institute is working to revolutionize treatment regimens for triple-negative breast cancer (TNBC) by proving that nebivolol, an FDA-approved drug for high blood pressure, is effective in treating it.

31 Jan 2024

Common biomarker test could be misguiding treatment for some Black women with breast cancer

A common test used to decide whether breast cancer patients should get chemotherapy may be making bad recommendations for some Black women, leading them to forgo chemotherapy when it might have helped, according to new research from the University of Illinois Chicago.

29 Jan 2024

Insilico Medicine leverages AI to identify promising new target for breast and gynecological cancers

Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1.

19 Jan 2024

Study highlights a potential new strategy to target triple-negative breast cancer

Cleveland Clinic researchers have successfully developed a therapeutic peptide that blocks aggressive cancer cells from multiplying rapidly.

17 Jan 2024

Combining immunotherapy and radiation to tackle aggressive triple-negative breast cancer

Cedars-Sinai Cancer investigators have analyzed the cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with different responses to the treatment.

8 Jan 2024

Internationally renowned breast medical oncologist joins the David Geffen School of Medicine at UCLA

Dr. Aditya Bardia, a renowned breast medical oncologist and physician scientist who specializes in developing novel targeted and personalized therapies, has joined the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center where he will assume several leadership roles across the institution.

14 Dec 2023

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.